Figure 2. MiR-613 rescues NUTM2A-AS1-regulated matrine resistance in GC cells. (A) StarBase 2.0 shows that miR-613 is a target of NUTM2A-AS1. (B) The reverse transcription-quantitative polymerase chain reaction was employed to evaluate the levels of miR-613 in N87 cells transfected with sh-NC, sh-NUTM2A-AS1-1, or sh-NUTM2A-AS1-1 plus the miR-613 inhibitor. ***P < 0.001. (C) The viability of N87 cells transfected with sh-NC, sh-NUTM2A-AS1-1, or sh-NUTM2A-AS1-1 plus the miR-613 inhibitor under matrine treatment was examined by using the MTT assay. *P < 0.05, **P < 0.01. (D, E) Cell colonies of N87 cells transfected with sh-NC, sh-NUTM2A-AS1-1, or sh-NUTM2A-AS1-1 plus the miR-613 inhibitor under matrine treatment. Scale bar, 5 μm. **P < 0.01, ***P < 0.001. (F, G) Apoptosis of N87 cells transfected with sh-NC, sh-NUTM2A-AS1-1, or sh-NUTM2A-AS1-1 plus the miR-613 inhibitor under matrine treatment was examined by using the TUNEL assay. Scale bar, 5 μm. **P < 0.01, ***P < 0.001. DAPI, 4',6-diamidino-2-phenylindole; NUTM2A, NUT family member 2A; AS1, antisense RNA 1; GC, gastric cancer; miR, microRNA; sh, small hairpin; NC, negative control; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.